浙江萃泽医药科技

Cuize Pharma is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of innovative small molecule drugs using protein degradation technology. The company's core focus is on its proprietary Proteolysis-Targeting Chimera (PROTAC) platform, which is designed to target undruggable proteins associated with cancer and autoimmune diseases. Founded in 2020 by Dr. Peng Wang, a veteran in the pharmaceutical industry with experience at GSK and Simcere, Cuize Pharma has rapidly advanced its lead candidate, CZ001, into Phase 1 clinical trials for prostate cancer. The company is supported by a strong syndicate of investors, including Qiming Venture Partners and Lilly Asia Ventures, to fuel its research and development pipeline. Cuize Pharma aims to address significant unmet medical needs by transforming the treatment landscape for patients with difficult-to-treat malignancies. Its integrated approach combines deep expertise in medicinal chemistry with advanced biological screening to discover next-generation therapeutics.